Welcome to the international HTA database

Showing [23537 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2020	The Regional Health Technology Assessment Centre (HTA-centrum)	Anti-inflammatory, antibiotic and immunomodulatory treatment in children with symptoms corresponding to the research condition PANS (Pediatric Acute-onset Neuropsychiatric Syndrome)
2020	NIHR Health Technology Assessment programme	An app-, web- and social support-based weight loss intervention for adults with obesity: the HelpMeDoIt! feasibility RCT
2020	NIHR Health Services and Delivery Research programme	The effects of interoperable information technology networks on patient safety: a realist synthesis
2020	Andalusian Health Technology Assessment Area (AETSA)	[Care model for women with endometriosis. Systematic review of clinical practice guidelines]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Daratumumab (newly diagnosed multiple myeloma, stem cell transplant unsuitable) - Addendum to Commission A20-14]
2020	The Regional Health Technology Assessment Centre (HTA-centrum)	Effectiveness of laminar versus turbulent airflow in operating theaters, with regard to risk for postoperative surgical infections
2020	European Network for Health Technology Assessment (EUnetHTA)	Rolling Collaborative Review COVID-19 - Lopinavir + Ritonavir
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Siponimod (multiple sclerosis) - Addendum to Commission A20-10]
2020	The Regional Health Technology Assessment Centre (HTA-centrum)	Update: Chlorhexidine wash prior to clean surgical procedures
2020	NIHR Health Services and Delivery Research programme	Social norms interventions to change clinical behaviour in health workers: a systematic review and meta-analysis
2020	Belgian Health Care Knowledge Centre (KCE)	Polyvalent immunoglobulins – Part 2: use in Belgium
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Daratumumab (newly diagnosed multiple myeloma, stem cell transplant suitable) - Addendum to Commission A20-15]
2020	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Efficacy and safety of active spiritual healing]
2020	The Regional Health Technology Assessment Centre (HTA-centrum)	Nature-based rehabilitation for patients with longstanding stress-related disorders – an updated report
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Brigatinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2020	The Regional Health Technology Assessment Centre (HTA-centrum)	Induction of labour at 41 or 42 weeks of gestation
2020	NIHR Health Technology Assessment programme	Gabapentin to reduce pain in women aged between 18 and 50 years with chronic pelvic pain: the GaPP2 RCT
2020	Malaysian Health Technology Assessment (MaHTAS)	Prophylactic anticoagulation in ambulatory cancer patients
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ribociclib (breast cancer, combination with an aromatase inhibitor) - Addendum to commission A20-21]
2020	NIHR Health Technology Assessment programme	Ursodeoxycholic acid to reduce adverse perinatal outcomes for intrahepatic cholestasis of pregnancy: the PITCHES RCT
2020	Norwegian Institute of Public Health (NIPH)	[Intermittent pneumatic compression for preventing deep vein thrombosis in acute stroke, a health technology assessment]
2020	Malaysian Health Technology Assessment (MaHTAS)	Antifibrotic for treatment of idiopathic pulmonary fibrosis
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Atezolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ribociclib (breast cancer, combination with fulvestrant) - Addendum to commission A20-22]
2020	Norwegian Institute of Public Health (NIPH)	[Effectiveness of microwave thermotherapy (TUMT) compared to transurethral resection of the prostate (TURP) for benign prostatic hyperplasia]
2020	Malaysian Health Technology Assessment (MaHTAS)	Needleless Vacutainer system for blood collection
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Darolutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2020	NIHR Health Services and Delivery Research programme	Variations in the organisation of Early Pregnancy Assessment Units (EPAUs) in the UK and their effects on clinical, service and patient-centred outcomes (VESPA)
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Apalutamide (prostate cancer) - Addendum to Commission A20-20]
2020	NIHR Health Technology Assessment programme	Rapid antigen detection and molecular tests for group A streptococcal infections for acute sore throat: systematic reviews and economic evaluation
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Apremilast (Behçet’s disease) - Benefit assessment according to §35a Social Code Book V]
2020	Scottish Health Technologies Group (SHTG)	The SARUS (safer - airway - resuscitation) - CPR hood to protect first responders from biohazards
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Solriamfetol (narcolepsy) - Benefit assessment according to §35a Social Code Book V]
2020	Scottish Health Technologies Group (SHTG)	Dxcover brain cancer liquid biopsy test for early brain cancer detection in primary care
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Naldemedine (opioid-induced constipation) - Benefit assessment according to §35a Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Romosozumab (osteoporosis) - Addendum to Commission A20-24]
2020	National Committee for Technology Incorporation (CONITEC)	[Dolutegravir for the treatment of pregnant women living with HIV]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ponatinib (chronic myeloid leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2020	National Committee for Technology Incorporation (CONITEC)	[Baricitinib (Olumiant) for patients with moderate to severe active rheumatoid arthritis]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ponatinib (Philadelphia chromosome positive acute lymphoblastic leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2020	Agency for Healthcare Research and Quality (AHRQ)	Care interventions for people living with dementia and their caregivers
2020	NIHR Health Technology Assessment programme	A systematic review of psychological interventions to improve motivation for self-management in people with type 1 and type 2 diabetes
2020	National Committee for Technology Incorporation (CONITEC)	[Mirabegron for the treatment of storage dysfunction in patients with neurogenic bladder]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Talazoparib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2020	NIHR Health Services and Delivery Research programme	Using co-production to improve patient carer and staff experiences in health care organizations: a multi-centre, mixed methods evaluation in inpatient stroke units (CREATE)
2020	National Committee for Technology Incorporation (CONITEC)	[Antimuscarinics (oxybutynin, tolterodine, solifenacin and darifenacin) for the treatment of storage dysfunction in patients with neurogenic bladder]
2020	Agency for Healthcare Research and Quality (AHRQ)	Characteristics of existing asthma self-management education packages
2020	National Committee for Technology Incorporation (CONITEC)	[Photodynamic therapy for non-melanoma skin cancer]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Mogamulizumab (mycosis fungoides or Sézary syndrome) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	National Committee for Technology Incorporation (CONITEC)	[Newborn screening for congenital toxoplasmosis]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Brentuximab vedotin (systemic anaplastic large cell lymphoma, first line) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	Agency for Healthcare Research and Quality (AHRQ)	Diagnosis and treatment of clinical Alzheimer's-type dmentia
2020	NIHR Public Health Research (PHR) programme	A woman-centred, tailored SMS-delivered multi-component intervention for weight loss and maintenance of weight loss in the postpartum period: intervention adaptation and pilot RCT
2020	National Committee for Technology Incorporation (CONITEC)	[Riociguat for inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension after surgical treatment]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Trifluridine/tipiracil (colorectal cancer) - Addendum to Commission A20-35]
2020	National Committee for Technology Incorporation (CONITEC)	[Orlistat for weight loss in overweight or obese patients]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Onasemnogene abeparvovec (spinal muscular atrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	Health Information and Quality Authority (HIQA)	Clinical guidelines for the management of massive haemorrhage – a systematic review
2020	NIHR Public Health Research (PHR) programme	A two arm feasibility trial of lifestyle information and Slimming World groups to promote weight management and positive lifestyle behaviour in postnatal women from an ethnically diverse inner city population
2020	National Committee for Technology Incorporation (CONITEC)	[Sibutramine for the treatment of obese patients]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Venetoclax (chronic lymphocytic leukaemia) - Addendum to Commission A20-39]
2020	Health Information and Quality Authority (HIQA)	Intraoperative massive haemorrhage– Irish incidence
2020	National Committee for Technology Incorporation (CONITEC)	[Empagliflozin and dapagliflozin for the treatment of type 2 diabetes mellitus]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42]
2020	NIHR Health Services and Delivery Research programme	Evaluating the use of patient experience data to improve the quality of inpatient mental health care
2020	NIHR Health Technology Assessment programme	Interventions based on early intensive applied behaviour analysis for autistic children: a systematic review and cost-effectiveness analysis
2020	National Committee for Technology Incorporation (CONITEC)	[Rifapentine plus isoniazid for treatment of latent mycobacterium tuberculosis infection (LTBI)]
2020	NIHR Health Technology Assessment programme	An extended stroke rehabilitation service for people who have had a stroke: the EXTRAS RCT
2020	NIHR Health Technology Assessment programme	Robot-assisted training compared with an enhanced upper limb therapy programme and with usual care for upper limb functional limitation after stroke: the RATULS three-group RCT
2020	National Committee for Technology Incorporation (CONITEC)	[Tofacitinib citrate for the treatment of moderate to severe ulcerative colitis in adult patients with inadequate response, loss of response or intolerance to previous treatment with conventional synthetic or biological drugs]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Darolutamide (prostate cancer) - Addendum to Commission A20-43]
2020	National Committee for Technology Incorporation (CONITEC)	[Expansion of the use of sirolimus for the treatment of adult patients with lymphangioleiomyomatosis]
2020	Agency for Care Effectiveness (ACE)	Acupuncture for adults with low back pain and neck pain
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (cystic fibrosis, 6 months to < 18 years, with R117H mutation)- Benefit assessment according to §35a Social Code Book V]
2020	NIHR Public Health Research (PHR) programme	The effectiveness of promotional campaigns associated with revised UK drinking guidelines: a prospective evaluation
2020	National Committee for Technology Incorporation (CONITEC)	[Targeted therapies (vemurafenib, dabrafenib, cobimetinib, trametinib) and immunotherapies (ipilimumab, nivolumab, pembrolizumab) for the first-line treatment of advanced (unresectable and metastatic) melanoma]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tezacaftor/ivacaftor (combination with ivacaftor; cystic fibrosis, 12 years and older, F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2020	NIHR Health Technology Assessment programme	Computerised speech and language therapy or attention control added to usual care for people with long-term post-stroke aphasia: the Big CACTUS three-arm RCT
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tezacaftor/ivacaftor (combination with ivacaftor; cystic fibrosis, 12 years and older, F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V]
2020	Health Information and Quality Authority (HIQA)	Evidence summary of potential for children to contribute to transmission of SARS-CoV-2
2020	NIHR Health Technology Assessment programme	Risk-based, 6-monthly and 24-monthly dental check-ups for adults: the INTERVAL three-arm RCT
2020	National Committee for Technology Incorporation (CONITEC)	[Personal frequency modulation system for hearing-impaired students at any age and at any academic level]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fostamatinib (chronic immune thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2020	Agency for Healthcare Research and Quality (AHRQ)	Impact of community health worker certification on workforce and service delivery for asthma and other selected chronic diseases
2020	Health Information and Quality Authority (HIQA)	Evidence summary for face mask use by healthy people in the community
2020	National Committee for Technology Incorporation (CONITEC)	[Cytoreductive surgery with hyperthermic chemotherapy in patients with malignant peritoneal mesothelioma]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Encorafenib (colorectal cancer) - Benefit assessment according to §35a Social Code Book V]
2020	Health Information and Quality Authority (HIQA)	Evidence summary of reinfection and the duration of antibody responses following SARS-CoV-2 infection
2020	National Committee for Technology Incorporation (CONITEC)	[Cytoreductive surgery (peritonectomy) with hyperthermic intraperitoneal chemotherapy (HIPEC)]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Scientific elaboration of a concept for an application-accompanying data collection and analysis for the drug onasemnogene abeparvovec in order to prepare a decision according to §35a (3b) Social Code Book V - Rapid report]
2020	Health Information and Quality Authority (HIQA)	Systematic review of the efficacy, effectiveness and safety of newer and enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over
2020	National Committee for Technology Incorporation (CONITEC)	[Exclusion of rifampicin for chemoprophylaxis for contacts of patients with Hansen´s disease]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Caplacizumab (acquired thrombotic thrombocytopenic purpura) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2020	Health Information and Quality Authority (HIQA)	Guidelines for the economic evaluation of health technologies in Ireland
2020	National Committee for Technology Incorporation (CONITEC)	[Ruxolitinib for the treatment of patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis, in people with intermediate-2 or high-risk disease]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Osilodrostat (endogenous Cushing syndrome) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2020	NIHR Health Technology Assessment programme	Sodium bicarbonate to improve physical function in patients over 60 years with advanced chronic kidney disease: the BiCARB RCT
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ozanimod (relapsing remitting multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2020	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Fall-safe assist. Portable device for falls prevention]